Arbutus Biopharma Corp 2025年季度报告

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch31, 2025 OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) 701 Veterans Circle,Warminster,PA18974 (Address of Principal Executive Offices and Zip Code)267-469-0914 Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Shares, without par valueABUSThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.Large accelerated filerAccelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). As of May12, 2025, the registrant had191,527,129common shares, without par value, outstanding. ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKITEM 4.CONTROLS AND PROCEDURES ITEM 2.ITEM 3. Effect of foreign exchange rate changes on cash and cash equivalents Increase in cash and cash equivalentsCash and cash equivalents, beginning of period Cash and cash equivalents, end of period 5 1.Nature of business and future operations Description of the Business ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B The Company continues to protect and defend its intellectual property, which is the subject of its ongoing lawsuits against Moderna patented lipid nanoparticle (LNP) delivery technology in their COVID-19 messenger ribonucleic acid interference (mRNA)-LNP vaccines.With respect to the Moderna lawsuit in the United States, a trial date has been set for September 29, 2025. With respect to thePfizer/BioNTech lawsuit, the claim construction hearing occurred in December 2024. The court is expected to provide its ruling on thePfizer/BioNTech lawsuit claim construction and issue a further scheduling order, including the date for trial, in 2025. On March 3, 2025, theCompany announced that, along with Genevant Sciences Ltd. (Genevant), it has filedfiveinternational lawsuits against Moderna inconnection with the use of the Company’s LNP technology in Moderna’s COVID-19 mRNA-LNP vaccines and, in the Unified Patent Court,also Moderna’s respiratory syncytial virus (RSV) vaccines. for the year ended December31, 2024 included in the Company’s Annual Report on Form 10-K for the year ended December31, 2024.These unaudited condensed consolidated financial statements include the accounts of Arbutus Biopharma Corporation and itsonewholly- owned subsidiary, Arbutus Biopharma, Inc., and reflect, in the opinion of management, all adjustments and reclassifications necessary tofairly present the Company’s financial position as of March31, 2025 and December31, 2024, the Company’s results of operations for thethree months ended March 31, 2025 and 2024, and the Company’s cash flows for the three months ended March 31, 2025 and 2024. Suchadjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2025 are not necessarilyindicative of the results for the full year. These unaudited condensed consolidated financial statements follow the same significant 6 Net loss per share is calculated based on the weighted average number of common shares outstanding. Diluted net loss per share does notdiffer from basic net loss per share for the three months ended March 31, 2025 and 2024, since the effect of including potential commonshares would be anti-dilutive. For the three months ended March 31, 2025, potential common shares of15.2 million pertaining tooutstanding stock options and unvested restricted stock units were excluded from the calculation of net loss per share. A total of Revenue from collaborations and licensesThe Company generates revenue through certain collaboration agreements and license agreements. Such agreements may require the development services, milestone payments and royalties.The Company’s collaboration agreements fall under the scope of Ac